Published in Curr Opin Drug Discov Devel on January 01, 2004
Use of cell viability assay data improves the prediction accuracy of conventional quantitative structure-activity relationship models of animal carcinogenicity. Environ Health Perspect (2008) 1.17
A novel two-step hierarchical quantitative structure-activity relationship modeling work flow for predicting acute toxicity of chemicals in rodents. Environ Health Perspect (2009) 0.93
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (2004) 21.39
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (2011) 4.06
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol (2012) 3.15
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos (2004) 3.00
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics (2004) 2.88
The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol (2012) 2.36
Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology (2013) 2.24
High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci (2009) 2.08
Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.95
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos (2005) 1.86
Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel (2010) 1.73
The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology (2007) 1.73
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos (2002) 1.70
Assessing the safety of stem cell therapeutics. Cell Stem Cell (2011) 1.60
Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. Am J Physiol Cell Physiol (2005) 1.59
Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica (2011) 1.57
Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med (2010) 1.54
Characterization of p-phenylenediamine-albumin binding sites and T-cell responses to hapten-modified protein. J Invest Dermatol (2009) 1.53
Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discov Today (2004) 1.49
Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem (2010) 1.47
Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov (2011) 1.45
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev (2007) 1.42
Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology (2004) 1.39
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer (2011) 1.38
Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J (2012) 1.37
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics (2006) 1.32
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol (2012) 1.28
Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel (2010) 1.28
Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem (2007) 1.27
Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem (2003) 1.26
Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics (2010) 1.24
Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. Toxicol Appl Pharmacol (2011) 1.21
Reporting of adverse drug reactions by nurses. Lancet (2003) 1.17
The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology (2008) 1.13
The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem (2010) 1.13
Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol (2005) 1.12
Role of Nrf2 in protection against acute kidney injury. Kidney Int (2013) 1.12
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology (2013) 1.10
Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today (2005) 1.09
Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem (2002) 1.09
Understanding the pathophysiological regulatory role of microRNAs in acute liver failure. Hepatology (2015) 1.09
Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol (2013) 1.08
Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol (2003) 1.08
Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells. Bioorg Med Chem (2008) 1.07
Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl (2010) 1.07
The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. Handb Exp Pharmacol (2010) 1.05
Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One (2012) 1.04
TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS (2002) 1.02
Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol (2007) 1.02
Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol (2006) 1.02
A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem (2006) 1.01
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem (2009) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem (2003) 1.00
Adverse drug reactions: back to the future. Br J Clin Pharmacol (2003) 1.00
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol (2013) 0.98
Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut (2010) 0.98
Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol (2010) 0.98
Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol (2002) 0.98
Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol (2011) 0.96
Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol (2007) 0.96
Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis (2010) 0.96
P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol (2010) 0.96
Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem (2012) 0.96
Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics (2006) 0.96
Biomarkers distinguish apoptotic and necrotic cell death during hepatic ischemia/reperfusion injury in mice. Liver Transpl (2014) 0.96
Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J (2006) 0.96
MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res (2008) 0.95
Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br J Clin Pharmacol (2014) 0.95
Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res (2010) 0.94
Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos (2010) 0.94
Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol (2011) 0.93
Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J Pharmacol Exp Ther (2011) 0.93
Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther (2003) 0.92
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol (2006) 0.92
Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-hydroxyethyl)deoxoartemisinin. J Med Chem (2004) 0.92
Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology (2013) 0.91
Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol (2009) 0.91
Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab Dispos (2010) 0.90
Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers. Biomarkers (2012) 0.90
Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel (2009) 0.90
Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. Biochem Pharmacol (2010) 0.89
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm (2010) 0.89
Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl (2009) 0.89
The danger hypothesis--potential role in idiosyncratic drug reactions. Toxicology (2002) 0.89
Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology (2003) 0.88
The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore. J Pharmacol Exp Ther (2007) 0.88
Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. J Proteome Res (2010) 0.88
Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol (2008) 0.88
Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther (2012) 0.87
A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics (2004) 0.87
Extract of Ginkgo biloba induces phase 2 genes through Keap1-Nrf2-ARE signaling pathway. Life Sci (2007) 0.87
Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity. Zebrafish (2014) 0.86
Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals. J Invest Dermatol (2010) 0.86
Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. Bioorg Med Chem (2010) 0.86
Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology (2007) 0.86